CNIH2: A Protein with Potential as A Drug Target and Biomarker

Target Name: CNIH2

NCBI ID: G254263

CNIH2

CNIH2: A Protein with Potential as A Drug Target and Biomarker

Cornichon-like protein (CNIH2) is a protein that is expressed in a variety of tissues, including the brain, pancreas, and heart. It is characterized by its unique structure, which is similar to that of cornichons, a type of small, edible fish.

One of the key features of CNIH2 is its ability to interact with a variety of molecules, including transcription factors, hormones, and signaling proteins. This interactivity makes CNIH2 an attractive target for drug development, as it suggests that the protein could be involved in a wide range of physiological processes.

In addition to its potential drug-target properties, CNIH2 is also being investigated as a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

The search for new drug targets and biomarkers is an important part of modern medicine, and CNIH2 is no exception. As more research is conducted on the protein, it is likely to gain more attention as a potential drug and biomarker.

One way that CNIH2 could be used as a drug target is by targeting its interaction with transcription factors. CNIH2 has been shown to interact with a variety of transcription factors, including those that control cell proliferation and differentiation. This suggests that CNIH2 could be involved in these processes and could be a useful target for drugs that target these processes.

Another potential way that CNIH2 could be used as a drug target is by targeting its role in signaling pathways. CNIH2 has been shown to interact with a variety of signaling proteins, including tyrosine kinases and G-protein-coupled receptors. This suggests that CNIH2 could be involved in signaling pathways and could be a useful target for drugs that target these processes.

In addition to its potential as a drug target, CNIH2 is also being investigated as a potential biomarker for a variety of diseases. For example, some studies have suggested that high levels of CNIH2 may be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Another potential application of CNIH2 as a biomarker is its role in the development of cardiovascular disease. Some studies have suggested that high levels of CNIH2 may be involved in the development and progression of cardiovascular disease, and that targeting the protein could be a useful way to diagnose and treat this disease.

Overall, CNIH2 is a protein that is being studied for its potential as a drug target and biomarker. As more research is conducted on the protein, it is likely to gain more attention as a potential source of new treatments and diagnostic tools for a wide range of diseases.

Protein Name: Cornichon Family AMPA Receptor Auxiliary Protein 2

Functions: Regulates the trafficking and gating properties of AMPA-selective glutamate receptors (AMPARs). Promotes their targeting to the cell membrane and synapses and modulates their gating properties by regulating their rates of activation, deactivation and desensitization. Blocks CACNG8-mediated resensitization of AMPA receptors

The "CNIH2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CNIH2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets